An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
Cell · 2025-08 · 188 (16) · 4225-4238.e12
DOI: 10.1016/j.cell.2025.05.038 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cell, 2025-08. Verfasst von Xiaobing Wang und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, National Key Laboratory for Immunity and Inflammation, Changzheng Hospital, Naval Medical University, Shan…. Hauptthemen laut MEDLINE: Antigens, CD19, Scleroderma, Systemic, Induced Pluripotent Stem Cells, Killer Cells, Natural. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: The National Key R&D Program of China, National Natural Science Foundation of China, the Clinical Research Project of the Shanghai Municipal Health Commission.
Abstract (Originalsprache)
This study reports the first-in-human application of iPSC-derived CD19/BCMA dual-targeting chimeric antigen receptor-natural killer (CAR-NK) cells (QN-139b) in a patient with severe, diffuse cutaneous systemic sclerosis. The allogeneic product was genetically edited for reduced alloreactivity and improved in vivo performance, with no structural chromosomal abnormalities detected. The treatment led to significant B cell depletion with minimal toxicity, similar to CAR T cell therapy. The patient showed marked clinical improvements during the 6-month follow-up, including reduced autoantibodies and reversed fibrosis, which are resistant to conventional treatments. Single-cell analysis of peripheral blood revealed that the treatment shifted B cells toward more naive phenotypes and eliminated pathogenic B cells. Proteomic studies demonstrated suppression of inflammation and fibrosis, enhanced tissue regeneration, and improved angiogenesis. Pathological evaluation confirmed the elimination of infiltrated lymphocytes from affected skin along with restored skin and microvascular structure. These findings suggest QN-139b is a promising immune-modulatory treatment for severe autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, National Key Laboratory for Immunity and Inflammation, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
- Department of Dermatology, Shanghai Key Laboratory of Medical Mycology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
- Department of Rheumatology and Immunology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
- Qihangene Biotech Co., Ltd, Hangzhou, Zhejiang 311200, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Institute of Genomic Medicine, Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
Förderung
- The National Key R&D Program of China
- National Natural Science Foundation of China
- the Clinical Research Project of the Shanghai Municipal Health Commission
- National Key Research and Development Program of China
- the Innovative Clinical Research Project of Shanghai Changzheng Hospital
- Shanghai Municipal Health Commission
Zitieren
APA
Wang, X., Zhang, Y., Jin, Y., Dai, L., Yue, Y., Hu, J., Liu, X., Pang, K., Ye, S., Chen, Y., Ye, W., Shi, X., Ma, X., Guo, L., Liu, Y., Ta, N., Zhu, X., Lin, L., Wang, J., …, & Xu, H. (2025). An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell, 188(16), 4225-4238.e12. https://doi.org/10.1016/j.cell.2025.05.038
Vancouver
Wang X, Zhang Y, Jin Y, Dai L, Yue Y, Hu J, et al. An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell. 2025;188(16):4225-4238.e12. doi:10.1016/j.cell.2025.05.038
BibTeX
@article{Wang2025,
author = {Wang, Xiaobing and Zhang, Yi and Jin, Yi and Dai, Lie and Yue, Yanan and Hu, Jiapan and Liu, Xin and Pang, Kun and Ye, Songying and Chen, Yue and Ye, Wenjing and Shi, Xiaofei and Ma, Xin and Guo, Lehang and Liu, Yanfang and Ta, Na and Zhu, Xiaofang and Lin, Li and Wang, Jiazheng and Yan, Ran and Wang, Ping and Song, Xiaobin and Zhou, Yixuan and Zhou, Lina and Wang, Qing and Guan, Tongxiang and Li, Ting and Zhou, Ling and Pan, Weihua and He, Yanran and Wu, Xin and Xu, Yingyong and Yang, Luhan and Xu, Huji},
title = {An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis},
journal = {Cell},
year = {2025},
volume = {188},
number = {16},
pages = {4225--4238.e12},
doi = {10.1016/j.cell.2025.05.038}
}
EUVIMED